The QualityStocks Daily Tuesday, August 16th, 2022

Today's Top 3 Investment Newsletters

CryptoCurrencyWire(GBOX) $1.9700 +55.12%

SeriousTraders(DSGT) $0.1190 +50.82%

MarketClub Analysis(BCAB) $11.8700 +48.38%

The QualityStocks Daily Stock List

VerifyMe Inc. (VRME)

QualityStocks, Wall Street Mover, MarketBeat, SmallCapVoice, PoliticsAndMyPortfolio and InvestorPlace reported earlier on VerifyMe Inc. (VRME), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

VerifyMe Inc. (NASDAQ: VRME) (FRA: LT1B) is a technology solutions firm that is engaged in the provision of digital and physical solutions and products that connect brands with consumers.

The firm has its headquarters in Rochester, New York and was incorporated in 1999, on November 10th by Norman A. Gardner. Prior to its name change in July 2015, the firm was known as LaserLock Technologies Inc. It operates as part of the security and protection services industry, under the industrials sector. The firm serves consumers around the world.

The enterprise is party to a strategic partnership with INX International Ink Co. Its solutions include a supply chain track and trace, serialization technology dubbed VerifyMe Track & Trace, which uses overt dynamic codes; and Engage services, which afford brand owners a chance to gather business intel and engage with their consumers using authentication tests. It also provides VerifyMe Authenticate services, which offer various tools via their patented products, including tamper proof labels known as VerifyLabel; a patented invisible ink dubbed VerifyInk; a device used with the VerifyMe App and a smartphone to authenticate and decode VerifyInk codes known as VerifyAuthenticator technology. In addition to this, it offers a handheld device that has been tuned to authenticate the unique frequency of VerifyInk, known as VerifyChecker.

The company recently expanded into the United Kingdom after entering into an agreement with a new cannabis firm which plans to purchase some of its products, including its tamper proof labels. This move allows the company to grow and extend its reach globally, which will be good for its revenues and investments.

VerifyMe Inc. (VRME), closed Tuesday's trading session at $2.32, up 41.4634%, on 13,195,676 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.47/$4.28.

Ecoark Holdings (ZEST)

QualityStocks and TopPennyStockMovers reported earlier on Ecoark Holdings (ZEST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ecoark Holdings Inc. (NASDAQ: ZEST) (FRA: P9Y) is a diversified holding firm that is engaged in the bitcoin mining, oil and gas and post-harvest freshness and shelf-life food management technology businesses.

The firm has its headquarters in San Antonio, Texas and was incorporated in 2007, on November 19th by Randy Scott May. It operates as part of the financial services industry, under the financials sector. The firm serves consumers in the United States.

The company operates through the Technology, Commodities and Financial services segments. The technology segment provides freshness management solutions for restaurants, grocers, fresh food growers, distributors, processors and suppliers. It has developed a cloud-based post-harvest shelf-life and freshness management solution dubbed the Fresh Solution, which improves the delivered freshness of protein and produce and decreases post-harvest losses at the retailer during processing and temperature handling. The Commodities segment is involved in gas and oil exploration, production and drilling operations at various properties in Mississippi, Louisiana and Texas. It also offers transportation of frac sand and logistics services to hydraulic drilling and fracturing operations. On the other hand, the financial segment is involved in Bitcoin mining. The company’s principal subsidiaries include Agora Digital Holdings Inc., Banner Midstream Corp and Ecoark Inc. It generates most of its revenues from the Commodities segment.

The enterprise, which recently provided an update to investors on its future plans, remains focused on generating long-term value for its shareholders. This will greatly benefit its stakeholders and help encourage more investments into the firm.

Ecoark Holdings (ZEST), closed Tuesday's trading session at $0.0188, up 30.5556%, on 46,483,479 volume. The average volume for the last 3 months is 336,729 and the stock's 52-week low/high is $1.59/$5.30.

Ultrapar Participacoes (UGP)

MarketBeat, InvestorPlace, Louis Navellier, MarketClub Analysis, All about trends, Zacks, Daily Trade Alert, Trades Of The Day, StreetInsider, Navellier Growth, TheStockAdvisors, TheStockAdvisor, Investiv, Hit and Run Candle Sticks, Short Term Wealth, StockTwits, Marketbeat.com, Dynamic Wealth Report, Direction Alerts and Uncommon Wisdom reported earlier on Ultrapar Participacoes (UGP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ultrapar Participacoes S.A. (NYSE: UGP) (FRA: UGR) (BVMF: UGPA3) (BCBA: UGP) is a holding firm focused on fuel distribution, gas distribution and storage businesses.

The firm has its headquarters in Sao Paulo, Brazil and was incorporated in 1937. It operates as part of the oil & gas refining and marketing industry, under the energy sector. The firm serves consumers around the globe, with a focus on those in Brazil, Venezuela, Uruguay, Mexico and other Latin American nations, Canada, the United States, Europe and the Far East.

The company operates through the Fuel Distribution, Gas Distribution, and Storage segments. The fuel distribution segment is involved in the marketing and distribution of ethanol, gasoline, fuel oil, diesel, natural gas for vehicles, kerosene and lubricants. It also provides automotive specialized services like lubricant changes, and operates convenience stores. The gas distribution segment is focused on distributing liquefied petroleum gas to industrial, commercial and residential consumers in the Northeast, Southeast and South regions of Brazil. On the other hand, the storage segment operates bulk liquid terminals primarily in the Northeast and Southeast regions of Brazil. In addition to this, the company provides a loyalty program known as Km de Vantagens; and operates a digital payments application known as Abastece Aí. The company’s subsidiaries include Serma-Associacao dos Usuarios de Equipamentos de Processamento de Dados e Serviços Correlatos and Imaven Imoveis Ltda.

The enterprise remains focused on maintaining a leadership position in its business segments and continuously innovating the development of new products and adoption of new operating technologies and procedures. This will enable the firm to extend its reach while also driving investments into the firm.

Ultrapar Participacoes (UGP), closed Tuesday's trading session at $7, up 29.6296%, on 28,604 volume. The average volume for the last 3 months is 36,968 and the stock's 52-week low/high is $2.135/$3.21.

Horizon Global (HZN)

MarketBeat, InvestorPlace, TradersPro, StreetInsider, StockMarketWatch, BUYINS.NET, Zacks, Trades Of The Day, Street Insider, PoliticsAndMyPortfolio, Marketbeat.com, Investing Lab and Daily Trade Alert reported earlier on Horizon Global (HZN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Horizon Global Corp. (NYSE: HZN) (FRA: 2H6) is focused on designing, manufacturing and distributing trailering, towing, cargo management and other related accessory products.

The firm has its headquarters in Plymouth, Michigan and was incorporated in 2015, on June 30th by Brian P. Campbell. It operates as part of the auto parts industry, under the consumer cyclical sector. The firm serves consumers across the globe.

The company operates through the Horizon Europe-Africa and the Horizon Americas segments. The Americas segment is involved in the sale of towing and trailering-related products through original equipment manufacturers, retail, e-commerce, aftermarket and industrial channels in South and North America. On the other hand, the Europe-Africa segment includes operations primarily in South Africa, Romania, U.K. France and Germany.

The enterprise offers towing products like gooseneck hitches, fifth wheels, hitches/tow bars, ball mounts, crossbars, wiring harnesses and other accessories. It also provides trailering products like interior and exterior vehicle lighting, couplers, winches, jacks and brake replacement parts. It also offers cargo management products like cargo carriers, roof cross bar systems, bike racks, luggage boxes, interior travel organizers, loading ramps and car interior protective products. The enterprise sells its products under the Reese, WesBar, Rola, Tekonsha, BTM, Reese Power Sports, Reese Explorer, Westfalia and Draw-Tite brands.

The company recently announced its latest financial results, with its CEO noting that they remained focused on improving their performance in their sales channels. This will positively influence revenues and investments into the company and help bolster its overall growth.

Horizon Global (HZN), closed Tuesday's trading session at $1.27, up 75.1483%, on 22,556,881 volume. The average volume for the last 3 months is 1.05M and the stock's 52-week low/high is $1.30/$8.75.

Teekay Corporation (TK)

Streetwise Reports, InvestorPlace, MarketBeat, VectorVest, StreetInsider, Barchart, StockMarketWatch, MarketClub Analysis, The Street Report, The Street, AllPennyStocks, BUYINS.NET, Vantage Wire, Investopedia, Zacks, SmallCapNetwork, SmarTrend Newsletters, Greenbackers, Marketbeat.com, Hit and Run Candle Sticks, Dividend Opportunities, Daily Trade Alert, ChartAdvisor, Investing Daily, Penny Stock Buzz, PoliticsAndMyPortfolio.com, QualityStocks, Schaeffer's, Street Insider, The Growth Stock Wire, The Online Investor, TopStockAnalysts, Trading Markets, Uncommon Wisdom, Wall Street Greek, Wall Street Mover, Wealth Insider Alert and Rick Saddler reported earlier on Teekay Corporation (TK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Teekay Corporation (NYSE: TK) (FRA: TCD) (BMV: TKN) is an investment holding firm that is engaged in the provision of crude oil and gas marine transportation services.

The firm has its headquarters in Hamilton, Bermuda and was incorporated in 1973 by Jens Torben Karlshoej. It operates as part of the oil and gas midstream industry, under the energy sector. The firm serves clients worldwide.

The company operates through the Teekay Parent, Teekay tankers and Teekay LNG segments. The parent segment owns FPSO units (floating production, storage and offloading units) as well as a minority investment in Tanker Investments Limited. The tankers segment is involving in providing conventional crude oil product carriers and tankers. On the other hand, the LNG segment consists of the liquefied petroleum gas and liquefied natural gas carriers.

The enterprise offers full suite ship-to-ship transfer services in the gas, oil and dry bulk industries. It also offers operational and maintenance marine services; lightering and lightering support services; and offshore production services. As of March 2022, the enterprise operated a fleet comprised of about fifty-five vessels. It primarily serves petroleum product producers, large oil consumers, major oil traders, energy and utility firms, government agencies and other entities which depend on marine transportation.

The firm continues to pursue future investments and remains focused on leveraging its operating franchise and its platform’s proven capabilities to create long-term value for its shareholders. This will drive investments and revenues into the firm and positively influence its growth.

Teekay Corporation (TK), closed Tuesday's trading session at $0.002, up 53.8462%, on 209,798,754 volume. The average volume for the last 3 months is 63,317 and the stock's 52-week low/high is $2.535/$4.01.

Odyssey Health Inc. (ODYY)

QualityStocks, SmallCapRelations, BioMedWire, InvestorBrandNetwork, Tiny Gems, Stocks to Buy Now, SeriousTraders, Penny Stock Titans, Wolf of Penny Stocks, Make Penny Stocks Great Again, Small Cap Firm, Fierce Analyst, Epic Stock Picks, Damn Good Penny Picks, Leading Penny Stocks, Insider Financial, MicroCapDaily, BeatPennyStocks, Penny Picks, StocksToBuyNow, StockWireNews, Tip.us, StockHideout, Great Penny Picks, Early Bird, TradersPro and ProTrader reported earlier on Odyssey Health Inc. (ODYY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The first case of COVID-19 was reported in Wuhan, China, in late 2019. In the following months, countries around the world shut down their borders as the virus infected millions of people.

Although the virus had a high survival rate of more than 90% in the United States, thousands of patients across the country began reporting coronavirus symptoms that lasted more than two months. Christened long COVID, this condition left patients suffering from symptoms such as cognitive dysfunction, shortness of breath, headache, chest pain and fatigue for up to three months after they contracted COVID-19.

According to a report from the Government Accountability Office, long COVID has potentially impacted up to 23 million U.S. citizens and pushed almost 1 million of them out of work.

An upcoming Denver university study seeks to determine whether there was a connection between a history of concussions and increased chances of developing long COVID. Researchers also hope that finding out more about the connection between concussions and long COVID-19 could open up new avenues for treating long-term coronavirus symptoms.

University of Denver professor Daniel Linseman posited that a brain that has already been subject to concussive stress will be more likely to develop long-COVID symptoms. Linseman studies injuries and diseases that cause cognitive degeneration. He and other researchers from the Englewood clinic Resilience Code and National Jewish Health will now have to enroll participants who have a history of concussions and those who don’t to see if Linseman’s theory holds water.

Linseman explained that some of the markers present in the blood of patients infected with the coronavirus are similar to the blood markers in concussed patients. Based on this, he theorizes that concussions and long-COVID may have some similarities in their underlying biology even if the two conditions affect patients in different ways.

Figuring out the biology behind these two conditions could make it possible for further research into drugs capable of treating the inflammation that is linked to long COVID. Linseman said that concussions leave lasting damage to the brain, making mitochondrial cells less efficient and causing them to produce more free radicals that damage other brain cells.

Chronic inflammation due to repeated concussions can also weaken the blood-brain barrier and make the brain more vulnerable to pollution and infection.

The upcoming study will focus more on the neurological symptoms associated with long COVID, such as brain fog, anxiety, depression and sleep disturbances and how a history of concussion increases one’s chances of developing long COVID.

Meanwhile, entities such as Odyssey Health Inc. (OTC: ODYY) are also focused on concussions but from a different angle. These companies want to develop novel treatments that target concussion and its neural effects because no current medication is specifically designed to address this clinical need.

Odyssey Health Inc. (ODYY), closed Tuesday's trading session at $0.3889, up 0.231959%, on 175,666 volume. The average volume for the last 3 months is 619,906 and the stock's 52-week low/high is $0.11/$0.64.

Southern Copper Corporation (SCCO)

SmarTrend Newsletters, MarketBeat, InvestorPlace, The Street, Louis Navellier, The Online Investor, Daily Wealth, Daily Trade Alert, The Wealth Report, TopStockAnalysts, Trades Of The Day, StreetAuthority Daily, Marketbeat.com, Zacks, Barchart, Money Morning, TheStockAdvisor, QualityStocks, Kiplinger Today, Schaeffer's, Market Intelligence Center Alert, MarketClub Analysis, Investopedia, Uncommon Wisdom, Top Pros' Top Picks, The Growth Stock Wire, Market Authority, The Stock Enthusiast, Early Bird, ChartAdvisor, TheStockAdvisors, INO.com Market Report, StreetInsider, InvestmentHouse, Investiv, Investing Futures, Greenbackers, Forbes, Investor Update, Dividend Opportunities, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, AllPennyStocks, DrStockPick, StockLockandLoad, Wealth Insider Alert, Wealth Daily, Vantage Wire, TradingMarkets, TradingAuthority Daily, The Tycoon Report, The Trading Report, The Motley Fool, MarketDNA, StockRockandRoll, InvestorGuide, StockHotTips, Profit Confidential, PennyToBuck, PennyOmega, Navellier Growth, Money and Markets, 24/7 Trader, InvestorsObserver Team, InvestorIntel and Streetwise Reports reported earlier on Southern Copper Corporation (SCCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The International Energy Agency predicted in its 2017 World Energy Outlook that by 2040, China may have exceeded the European Union’s energy consumption. In the report, the agency stated that electricity was the rising force among global end uses of energy, noting that it would make up 40% of the increase in final consumption by 2040. To help produce and distribute electricity in this new world, a recyclable and durable metal that possessed good electrical conduction properties would be needed.

This is why many expect that as the world enters a new era of technological innovation and international industrialization, the demand for copper will increase significantly. In a recent interview, a senior analyst at Stifel GMB stated that the current prediction of the price levels for copper were not sufficient enough to encourage more suppliers to come online in response to the expected increase in demand as more countries around the globe electrify their economies.

Egizio Bianchini, the head of metals and mining investment banking at Stifel, explained that company valuation multiples and the average price of the copper metal both need to increase considerably for the industry to attempt to deliver a stronger supply response to the demand expected. Bianchini, who is also the company’s vice chair, added that the international copper industry was undercapitalized and undersized to deliver an aggressive supply response to the expected increase in demand.

Bianchini explained that in spite of the high margins the sector was experiencing, the price of copper remained below incentive pricing when one took into account the various risk factors associated with the financing, development and construction of a mine in the present environment. These factors, which play a significant role in the development of mines, include additional unpredictable environmental regulations, worsening geopolitical environment, dramatically rising inflation for goods and services, high incentives for governments to control more resources via resource nationalism and the expanding timeframes for executing the development and construction of mines.

However, Bianchini also noted that despite these hitches in development, the price of copper appeared strong in comparison to trailing prices. He added that while it wasn’t that simple, forward-looking pricing expectations of copper appeared to be robust enough at face value to attract more suppliers and increase production.

Projections show that by 2023, the global market for the red metal may reach about $171 billion. Increasing electrification and emerging energy trends are expected to contribute greatly to this growth, which will afford suppliers new opportunities to generate revenue.

If production doesn’t increase in tandem with the growing demand, existing producers such as Southern Copper Corporation (NYSE: SCCO) may reap the rewards of being in the industry at a time when supply is tight and demand is soaring.

Southern Copper Corporation (SCCO), closed Tuesday's trading session at $2.51, off by 1.3054%, on 9,739 volume. The average volume for the last 3 months is 208,290 and the stock's 52-week low/high is $44.70/$79.315.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, QualityStocks, MarketBeat, Trades Of The Day, Kiplinger Today, Daily Trade Alert, The Online Investor, StocksEarning, Investopedia and Louis Navellier reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The automotive industry is currently in the midst of a major revolution as the number of electric vehicles on the road steadily increases. Rising electric vehicle adoption has led to a shift in consumer behavior, meaning automakers and car dealerships that wish to succeed will have to evolve their sales, marketing and customer experiences. So how exactly is EV adoption affecting consumer behavior?

For starters, plenty of drivers are no longer checking how many miles per gallon a car can travel or looking for sports packages. They are instead researching EV battery range, referring to how far a vehicle can travel on a single charge, the availability of reliable public charging networks, and the functionality of EV technology. In short, the factors that drivers usually considered when buying cars have changed dramatically.

This, in turn, has had a significant impact on purchasing behaviors that is shaking up the automotive industry. Unlike before, drivers are more conscious of the need for clean energy in the transportation sector. Furthermore, the rise of the EV industry, which has fought against using the conventional car dealership model, has increased the distaste and general distrust of the car-dealership experience.

Drivers are now more concerned about range, with more than 50% reporting that they feared running out of charge while on the road. Insufficient public charging infrastructure, coupled with faulty charging stations, has exacerbated range anxiety among drivers. The Fuel Institute estimates that most EV drivers now charge their cars at home overnight.

According to a New York Times article, Millennials are two times more likely to look for and buy a car online, signifying a major shift in car purchasing behavior. Millennials would like a system that offers more transparency regarding prices and a faster, less-complicated purchasing process. They don’t want to have to deal with sales pitches and long, convoluted processes when they buy their cars, and the online EV shopping experience offers that.

Automakers such as Tesla that have adopted an online purchasing model, are much more likely to attract these kinds of buyers and outcompete other carmakers. And as electric vehicles become more affordable, we can expect shifts in the demographic of buyers that are more likely to purchase EVs. Studies have shown that for the past decade, the electric vehicle market has been mainly filled with males aged 40 to 55 years with a yearly household income of more than $100,000.

More affordable EVs will result in a change in this demographic, with more millennials being able to purchase electric vehicles because they become more affordable, available, and familiar. Firms like Lucid Motors (NASDAQ: LCID) have their work cut out to tweak how they communicate with current and future customers in order to deepen EV penetration.

Lucid Motors (LCID), closed Tuesday's trading session at $5.63, up 0.356506%, on 21,984 volume. The average volume for the last 3 months is 902,542 and the stock's 52-week low/high is $13.25/$57.75.

DoubleDown Interactive Co. Ltd. (DDI)

QualityStocks, Zacks, MarketBeat and InvestorPlace reported earlier on DoubleDown Interactive Co. Ltd. (DDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DoubleDown Interactive (NASDAQ: DDI), a leading developer and publisher of digital social casino games, is commemorating 12 years since the unveiling of its flagship title, DoubleDown Casino. The celebration includes free prizes and a DoubleDown Birthday Bash on Aug. 26 and 27, 2022, during which players are encouraged to complete slot quests to earn a reward based on how many quests they complete. DoubleDown Casino features a variety of slot machines and table games designed to provide a Las Vegas casino experience virtually on mobile and desktop platforms. This social casino game includes authentic Las Vegas slot machines developed by International Game Technology PLC (“IGT”). Between casino titles and exclusive original slots, DoubleDown has a catalog of more than 200 slots for players to choose from. “DoubleDown Casino was one of the first games of its kind when it debuted in 2010,” said DoubleDown CEO In Keuk Kim in the press release. “We are honored that DoubleDown Casino has remained one of the leading games in the social casino space for the past 12 years, and we are grateful to all our passionate players, to whom we owe our longstanding success.”

To view the full press release, visit https://ibn.fm/dhjpd

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multiformat interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. DDI’s flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. For more information about the company, visit www.DoubleDownInteractive.com.

DoubleDown Interactive Co. Ltd. (DDI), closed Tuesday's trading session at $2.42, off by 0.819672%, on 5,384 volume. The average volume for the last 3 months is 12.998M and the stock's 52-week low/high is $8.31/$18.4999.

LiveOne Inc.'s (LVO)

QualityStocks and StocksEarning reported earlier on LiveOne Inc.'s (LVO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PodcastOne, a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), today announced its entry into a multiyear agreement with Kevin Connolly’s boutique media network ActionPark Media (“APM”), a Los Angeles based hub specializing in podcast creation. According to the update, the deal gives PodcastOne exclusive distribution and advertising sales rights for APM’s current slate of podcast and vodcast programming. It will also allow for the two media companies to co-develop future podcast/vodcast based IP, produce advertiser sponsored live streaming and touring opportunities for hosts/talent and create exclusive licensing for podcast specific branded merchandise. “Kevin and APM clearly have a knack for producing quality podcast content with Victory the Podcast being one of the first shows giving a behind the scenes look at a hit television series and The Morning After with Kelly Stafford consistently charting as one of the top shows for parents and families,” said Kit Gray, president of PodcastOne. “This joint venture now gives us the ability to work together to grow the audience for a slate of incredible existing shows. Additionally, with LiveOne’s streaming partnerships, live event capabilities and merchandising division, we are excited to further enhance branding opportunities for the star studded roster of hosts.”

To view the full press release, visit https://ibn.fm/HWGSG

About LiveOne Inc.

Headquartered in Los Angeles, California, LiveOne is an award-winning, creator-first, music, entertainment and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. The company was awarded Best Live Moment by Digiday for its “Social Gloves” PPV Event, and has been a finalist for 8 more awards, including Best Live Event, Best Virtual Event, Best Overall Social Media Excellence, and Best Original Programming from Cynopsis and Digiday . As of June 30, 2022, the company has accrued a paid and free membership base of over 2.37 million*, streamed over 2,900 artists, has a library of 30 million songs, 600 curated radio stations, over 300 podcasts/vodcasts, hundreds of pay-per-views, personalized merchandise, released music-related NFTs, and created a valuable connection between fans, brands and bands. The company’s wholly-owned subsidiaries include Slacker Radio, React Presents, Gramophone Media, Palm Beach Records, Custom Personalization Solutions, LiveXLive, PPVOne and PodcastOne, which generates more than 2.48 billion downloads per year and 300+ episodes distributed per week across its stable of top-rated podcasts. LiveOne is available on iOS, Android, Roku, Apple TV, Amazon Fire, and through OTT, STIRR, and XUMO. For more information, visit www.LiveOne.com.

*Included in the total number of paid members for the reported periods are certain members which are the subject of a contractual dispute. LiveOne is currently not recognizing revenue related to these members.

LiveOne Inc.'s (LVO), closed Tuesday's trading session at $2.91, up 1.0417%, on 961,817 volume. The average volume for the last 3 months is 5,311 and the stock's 52-week low/high is $0.560001/$3.57.

AmeriCann Inc. (ACAN)

QualityStocks, InvestorPlace, Promotion Stock Secrets, TopPennyStockMovers, Wall Street Mover, TheMicrocapNews, SmallCapVoice, Real Pennies, OTC Markets Group, MarketBeat and Cannabis Financial Network News reported earlier on AmeriCann Inc. (ACAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, has released its financial and operational results for its fiscal quarter ending June 30, 2022. According to the company, July revenue set an all-time monthly record. Numbers showed a significant increase in year-over-year quarterly net income and revenue, with both being records for the Company for the quarter ending June 2022. Revenue increased over 36% for the quarter ended June 2022 relative to the same quarter 2021, an increase of $213,188. Quarterly gross margins were 98.5%. The company attributed the increased revenue to products produced and manufactured at Building 1, AmeriCann’s initial building at its Massachusetts Cannabis Center development in Freetown, Massachusetts. The 30,000-square-foot cultivation greenhouse and processing facility features utilizes AmeriCann’s proprietary Cannopy cultivation system and is occupied by Bask Inc., an existing licensed vertically integrated cannabis operator in Massachusetts. AmeriCann receives base rent and a revenue participation fee of 15% of all gross monthly sales of cannabis, cannabis-infused products and noncannabis products produced at the Massachusetts Cannabis Center. The report noted that the manufacturing of cannabis-infused products, including the 1906 branded Drops, Howl’s Tincture and Harpoon Extracts, has increased dramatically at the center, with projected sales of manufactured infused products expected to be even stronger. “The June 2022 financial results highlight the strength of our operations,” said AmeriCann CEO and president Tim Keogh in the press release. “Record revenue, combined with our high gross margins and low operating costs, resulted in all-time profits and cash flow for the company. Additionally, July 2022 revenue, which was not included in the most recent quarterly financials, set a monthly record.”

To view the full press release, visit https://ibn.fm/bMLis

About AmeriCann Inc.

AmeriCann develops and leases cannabis cultivation, processing and product manufacturing facilities. The company uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights and utility bills are up to 75% less than in typical warehouse cultivation facilities. As such, AmeriCann's Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP-certified cannabis extraction and product manufacturing infrastructure. The company has secured licenses to produce cannabis-infused products, including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, please visit www.Americann.co.

AmeriCann Inc. (ACAN), closed Tuesday's trading session at $30.5, off by 3.5421%, on 16,050,569 volume. The average volume for the last 3 months is 964,618 and the stock's 52-week low/high is $0.30/$0.949.

Treasure Global Inc. (TGL)

Super Stock Picker and Streetwise Reports reported earlier on Treasure Global Inc. (TGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Treasure Global (NASDAQ: TGL), an innovative e-commerce platform providing seamless payment solutions and rewards programs, has closed on its previously announced upsized initial public offering. The offering comprised 2,300,000 shares of common stock and included the full exercise of the underwriter’s overallotment option; the shares were offered at $4 per share, resulting in gross proceeds of some $9.2 million before deducting underwriting discounts, commissions and other offering expenses. The announcement noted that TGL common stock began trading on the Nasdaq Capital Market on Aug. 11, 2022. According to the announcement, Treasure Global plans to use the net proceeds from the offering to increase its capitalization and financial flexibility, as well as for working capital and general corporate purposes.

To view the full press release, visit https://ibn.fm/ukwAZ

About Treasure Global Inc.

TGI is an innovative Malaysian e-commerce platform providing seamless payment solutions for consumers and merchants with instant rebates and affiliate cashback programs. On a mission to bring together the worlds of online e-commerce and offline physical retailers, TGI is developing a portfolio of leading digital platforms for use throughout Southeast Asia (“SEA”) and Japan. In June 2020, TGI launched its proprietary product, the ZCITY App, a unique digital ecosystem that transforms and simplifies the e-payment experience for consumers, while simultaneously allowing them to earn rewards. In the ZCITY ecosystem, users can utilize Tazte, a revenue-generating digital F&B management system providing merchants with a one-stop touchless management and automated solution to digitalize their businesses. As of July 2022, ZCITY had more than 2,000,000 registered users and more than 2,100 registered merchants. For more information about the company, visit www.TreasureGlobal.co.

Treasure Global Inc. (TGL), closed Tuesday's trading session at $6.75, off by 1.4599%, on 3,383 volume. The average volume for the last 3 months is 1,745 and the stock's 52-week low/high is $4.55/$19.80.

The QualityStocks Company Corner

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight Cerberus Cyber Sentinel Corp. (NASDAQ: CISO).

  • Cerberus Sentinel shares were listed on the Nasdaq in the first quarter of 2022
  • The company joined the broad-market Russell 2000 Index in June 2022
  • Cerberus Sentinel posted a 376% revenue CAGR for the years 2019 through 2021
  • In 2021, 58% of the company’s revenue was recurring revenue from managed services contracts
  • Cerberus Sentinel has completed 12 strategic acquisitions since October 2019
  • The global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period

Cerberus Cyber Sentinel (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, Cerberus helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, Cerberus Sentinel has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, Cerberus helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, Cerberus Sentinel has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The Cerberus Sentinel workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

Cerberus Sentinel has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, Cerberus Sentinel works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, Cerberus Sentinel helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, Cerberus Sentinel seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. Cerberus Sentinel believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

Cerberus Sentinel’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, Cerberus Sentinel customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of Cerberus Sentinel. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at Cerberus Sentinel. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining Cerberus Sentinel, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at Cerberus Sentinel. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining Cerberus, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at Cerberus Sentinel. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO), closed Tuesday's trading session at $2.47, up 13.8249%, on 38,478 volume. The average volume for the last 3 months is 4.985M and the stock's 52-week low/high is $2.61/$49.00.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth (NASDAQ: FLGC), a manufacturer and distributor of global cannabis products and brands, is reporting its financial and corporate results for the six months ending June 30, 2022. Highlights of the report include revenue for the company increasing 604% from the same period last year, reaching ~$15 million while gross profit for the company increased to ~$7 million, an increase of 547%. In the report, the company reaffirmed its 2022 revenue guidance of $35 million to $45 million, which represents an increase in projected revenue of between 300% to 400%. “In the first half of 2022, Flora delivered on its promise to double revenue compared to the second half of 2021, and we expect to maintain that trajectory to deliver our full year guidance as a result of continued growth in our House of Brands, the launch of several new brands in the United States, and the commencement of sales in our Commercial Wholesale and Life Sciences business,” said Flora Growth CEO and chair Luis Merchan in the press release. “We started 2022 with the integration of both Vessel and JustCBD, and despite macro headwinds in the global markets as well as global cannabis regulations, we are extremely pleased with our growth year-to-date. We are also seeing positive movement in our Life Sciences division with progress on the approval of our clinical trials in the United Kingdom and the acquisition of Masaya, a science-backed, high-potency CBD brand. . . . We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward. With all three of our core pillars generating revenue in the second half of 2022, continued gross margin expansion and a focus on streamlining operating expenses, we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment.” To view the full press release, visit https://ibn.fm/pvrWP

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $2.17, up 5.3398%, on 52,316 volume. The average volume for the last 3 months is 130,328 and the stock's 52-week low/high is $0.586/$21.45.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information circular were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. To view the full press release, visit https://ibn.fm/VBYYH

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.86, up 10.3979%, on 1,052,894 volume. The average volume for the last 3 months is 864,342 and the stock's 52-week low/high is $0.3903/$2.88.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted by best-selling author and entrepreneur Dr. Anthony M. Criniti IV (aka “Dr. Finance(R)”). During the interview, Favre discussed how his passion for uncovering a treatment for concussion led him to his current position as a member of Odyssey Health’s sports advisory board. “When I retired for good in 2011 after 20 years, I had something to fall back on, obviously, my family… but I don’t want to own businesses and lead 500 employees. That’s not my cup of tea,” Favre said. “Really what I’m most passionate about now is [uncovering a concussion treatment] … The very last play of my career was a major concussion. I don’t want to act like I’m an expert in concussions, but I do know this: there is never a good time to have a major concussion. What little bit we know about concussions compared to when I first started playing in 1991 is that they’re terrible, and the repercussions can be anything from death to all kinds of mental illnesses.” To view the full press release, visit https://ibn.fm/FBn16. The first case of COVID-19 was reported in Wuhan, China, in late 2019. In the following months, countries around the world shut down their borders as the virus infected millions of people. Although the virus had a high survival rate of more than 90% in the United States, thousands of patients across the country began reporting coronavirus symptoms that lasted more than two months. Christened long COVID, this condition left patients suffering from symptoms such as cognitive dysfunction, shortness of breath, headache, chest pain and fatigue for up to three months after they contracted COVID-19. According to a report from the Government Accountability Office, long COVID has potentially impacted up to 23 million U.S. citizens and pushed almost 1 million of them out of work. Meanwhile, entities such as Odyssey Health Inc. (OTC: ODYY) are also focused on concussions but from a different angle. These companies want to develop novel treatments that target concussion and its neural effects because no current medication is specifically designed to address this clinical need.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Tuesday's trading session at $0.2589, up 1.2911%, on 217,826 volume. The average volume for the last 3 months is 672,748 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Cannabis reform is still quite controversial. Reform activists have had a hard time getting reform past lawmakers who oppose cannabis for a variety of reasons. In many cases, they have been forced to give up certain provisions in their cannabis initiatives to make them more palatable to Republican and Democratic lawmakers who were withholding their support. A recent report from the Senate Intelligence Committee has revealed that the panel did just that last month. In late June, the Senate committee voted in favor of a measure that would make it possible for people who had used cannabis in the past to work for intelligence agencies such as the Central Intelligence Agency (CIA) and the National Security Agency (NSA). The measure was then attached to the Intelligence Authorization Act, which was slated to go through both chambers before reaching the president’s desk. However, the report says that the committee adopted a scaled-back version of the original proposal instead. While the cannabis industry and its actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would have preferred to see sweeping marijuana reforms at the federal level, the incremental approach now seems the more realistic way, and advocates need to exercise patience as the process plays out over time.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Tuesday's trading session at $4.08, even for the day, on 15,148 volume. The average volume for the last 3 months is 1.058M and the stock's 52-week low/high is $0.0099/$0.0694.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

  • Irregular weather and climate patterns reported to be caused by excess atmospheric carbon
  • Net-Zero refers to atmospheric state where carbon added to atmosphere is less than carbon removed, concept emerged at 2015 UN Climate Change Conference
  • GeoSolar’s Smart Green™ systems use solar panels and geothermal ground loops to generate power from renewable sources, enables residents and businesses to achieve Net-Zero ahead of government targets
  • Company recently qualified by SEC to conduct Regulation A+ capital raise, plans to file for OTCQB listing

Rising temperatures, fierce storms, colder winters, and other irregular weather patterns are prompting citizens, businesses, and governments to take action that balances carbon dioxide (“CO2”) in the atmosphere. Referred to as “Net-Zero”, this ambitious goal aims to achieve carbon neutrality by limiting CO2-releasing activities associated with manufacturing, transportation, agriculture, and energy production. GeoSolar Technologies (“GST”), a Colorado-based climate technology company, empowers residents and businesses to achieve Net-Zero with its Smart Green™ systems that leverage the power of the sun and earth to heat and cool buildings, charge electric vehicles, and run electric appliances. Smart Green™ systems also purify the air to maintain quality control standards while reducing or eliminating carbon emissions and maximizing energy efficiency.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

  • This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families.
  • “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO.
  • Patent covers formulation and preparation of CycloSam in the U.S.

QSAM Biosciences (OTCQB: QSAM) has been awarded a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R). Granted by the U.S. Patent & Trademark Office, the patent “protects how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs” (https://ibn.fm/J5Gvz). QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate CycloSam, its proprietary radiopharmaceutical drug candidate for the treatment of metastatic bone cancer. Specifically, the report noted that preliminary evaluation of the first patient dosed in the phase 1 trial suggests promising results with second patient dosing and completion of the first cohort of patients in the trial is expected in the third calendar quarter along with additional clinical trial sites and nuclear reactor sites. The company also noted that it received a third key U.S. patent covering the production and delivery of CycloSam, further strengthening its extensive patent portfolio. Financial results show a $1.33 million net loss attributable to common stockholders for the quarter, along with operating expenses totaling $1.26 million for the quarter and an increase in professional fees of $0.07 million related to QSAM’s terminated public offering. “We are encouraged by the initial, preliminary data from the first patient dosed with CycloSam,” said QSAM Biosciences cofounder and CEO Douglas R. Baum in the press release. “While it is too early for formal conclusions to be made of these early results, we did see positive signals in terms of safety and efficacy. CycloSam performed how we expected it to perform, even given the lowest dosage in our dose-escalating study. Over the next few months, we expect to make steady progress in our first clinical trial, including establishing additional trial sites that will help us treat more patients, and qualifying additional nuclear reactors to build redundancy and efficiencies in our supply chain. . . . Our decision to postpone our planned equity raise and NASDAQ uplisting in May was based on market conditions at that time. We are now seeing the beginnings of a turnaround in the broader biotech markets. If these continue, and we achieve the progress we expect in our clinical trials over the next six months, we intend to revisit the uplisting process in early 2023. We are actively working toward creating shareholder value in conjunction with our most important mission to help adult and pediatric patients suffering from bone cancer.” To view the full press release, visit https://ibn.fm/DBGPA.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Tuesday's trading session at $, even for the day. The average volume for the last 3 months is 113 and the stock's 52-week low/high is $3.50/$20.40.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. EverGen’s co-founder and CEO Chase Edgelow joined the latest episode to discuss the company’s recent corporate milestones, beginning with its May acquisition of a 50% interest in Project Radius. “Project Radius is a mark of our expansion across Canada, continuing to build our renewable natural gas (‘RNG’) platform with three large-scale RNG projects that have the capability of producing almost two million gigajoules per year once they are up-and-running,” Edgelow said. “Renewable natural gas, in Canada and the U.S., is a market that’s really starting to pick up steam. The gas utilities on both sides of Canada – the West Coast and Quebec – have both set targets of 15-20% of their volume to come from RNG or renewable products by 2030.” To view the full press release, visit https://ibn.fm/w5liA

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Tuesday's trading session at $0.34454, off by 4.2944%, on 177,898 volume. The average volume for the last 3 months is 10 and the stock's 52-week low/high is $2.12/$4.21.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate Infrastructure Partners (OTCQB: CIPI) is a technology-enabled energy optimization and clean energy solutions provider for the North American real estate industry. The company today reported financial results for its second quarter ended June 30, 2022, and year to date ended June 30, 2022. “We continue to grow as a full-service energy optimization service provider, and we are realizing many near-term opportunities for Correlate. By helping commercial customers increase net operating income (‘NOI’) through our clean energy solutions, the benefits of our innovative full-service platform becomes a more integral part of real estate asset management,” said Correlate CEO Todd Michaels. “We are also actively maturing our aggressive acquisition strategy by identifying targets that complement our technology stack or provide fulfillment capabilities in key regions.” To view the full press release, visit https://ibn.fm/2em2a

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Tuesday's trading session at $0.22, off by 5.1724%, on 11,405 volume. The average volume for the last 3 months is 1,300 and the stock's 52-week low/high is $0.3021/$3.25.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S
  • According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September
  • In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn
  • In the longer term, the company is targeting milestone payments from large national and international consumer companies and pharmaceutical organizations

In a June 7 Fireside Chat hosted by John D. Vandermosten, CFA, of Zacks Small-Cap Research (“SCR”), Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka expressed hope that the then-ongoing negotiations with “national players in different areas of the world” would yield contracts that would significantly improve its revenue (https://ibn.fm/qhlo1). The negotiations led to separate announcements that form the basis of Zacks SCR’s latest coverage of the company, who value Lexaria at $15 per share (https://ibn.fm/OvOaJ).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $0.17, off by 2.6346%, on 1,099,775 volume. The average volume for the last 3 months is 51,009 and the stock's 52-week low/high is $1.85/$7.20.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

  • Dr. Liqun Han has been appointed as Cepton’s COO, having led the Company’s product development, commercialization, and operations teams over the past several years
  • The announcement marks a momentous year for the Company, with Cepton recently revealing that it had opened an expanded office within the Metro Detroit area to strengthen its engagements with automotive OEMs
  • Cepton attended the J.P. Morgan Auto Conference on August 10, 2022, where they hosted a live presentation for potential investors and other interested parties

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, announced that they appointed Dr. Han to the position of Chief Operating Officer (“COO”). Dr. Han previously led Cepton’s product development, commercialization, and operational excellence teams since 2016 as Senior Vice President of Operations, and this promotion will accelerate the Company’s efforts in market commercialization and series production readiness. Prior to Cepton, Dr. Han served as Director of Engineering and Technology at KLA-Tencor where he was responsible for core technology innovation and new product introduction. Dr. Han received a Ph.D. in Applied Physics and a M.S. in Electrical Engineering from Stanford University, with a specialty in solid-state electronics and optics.

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Tuesday's trading session at $0.1305, off by 1.5094%, on 5,864 volume. The average volume for the last 3 months is 392,401 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, have announced advanced appointments for two key executives. According to the company, Delic Holdings cofounder and CEO Matt Stang has been named executive chair while COO Kevin Nicholson has been named CEO and will also join the company’s board of directors; Nicholson will continue to serve in his current role as CEO of Ketamine Wellness Centers (“KWC”). Before founding Delic, Stang owned and operated “High Times,”a leading source of cannabis news. As Delic CEO, Stang led the company in its acquisition of KWC, becoming the nation's largest ketamine therapy provider in the process. Under his leadership, DELCF repported more than $1.5 million in revenue last year and increased net assets 500% in its first full year of operation. In his role as CEO of KWC, Nicholson grew the company, which generated an annual revenue of more than $4 million and provided some 100,000 treatments to date. The company also noted that it has granted 4,600,000 stock options to certain officers, directors, employees and consultants to purchase 4,600,000 subordinate voting shares. “As the conversation around psychedelics evolves and gains momentum, Delic will continue to remain at the forefront,” said Delic Holdings executive chair Matt Stang in the press release. “It is a privilege to continue as the company's executive chairman and to work closely with the prestigious board of directors under Kevin's leadership. I am highly confident that together we will continue to guide the company in its next phase of growth and further modernize healthcare.” To view the full press release, visit https://ibn.fm/7EHKF. Initial studies have found that certain psychedelics have plenty of potential as treatments for mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder. Furthermore, activists across the country have put forth a variety of measures to decriminalize psychedelics, with cities such as Denver moving to decriminalize all psychedelics. But before psychedelics can be approved for widespread medical use, they will have to go through the clinical trial system successfully. This process involves three phases: phase I trials where animals are used to test the efficacy and safety of drugs; phase 2 trials involving several dozen patients with a specific condition such as PTSD; phase 3 trials where the safety and efficacy of the drug are tested in a large group of people, usually more than 100 patients. This particular ketamine study could take the activities of companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) in an additional direction once the trial yields positive results for the treatment of AUD.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.0767, off by 4.8387%, on 28,360 volume. The average volume for the last 3 months is 22,300 and the stock's 52-week low/high is $0.03/$0.3139.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.